| 0.855 -0.115 (-11.86%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.28 | 1-year : | 1.63 |
| Resists | First : | 1.09 | Second : | 1.39 |
| Pivot price | 0.95  |
|||
| Supports | First : | 0.61 | Second : | 0.5 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 0.89 |
| MA(100) : | 0.63 |
MA(250) : | 0.71 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 30.6 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 1.73 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABVC ] has closed above bottom band by 31.5%. Bollinger Bands are 111.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.96 | 0.96 - 0.96 |
| Low: | 0.84 - 0.84 | 0.84 - 0.85 |
| Close: | 0.85 - 0.86 | 0.86 - 0.86 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Tue, 15 Apr 2025
ABVC BioPharma Reports Strong Financial Growth - TipRanks
Tue, 15 Apr 2025
ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
Tue, 15 Apr 2025
ABVC BIOPHARMA, INC. SEC 10-K Report - TradingView
Mon, 31 Mar 2025
ABVC BioPharma Delays Yearly Report Filing - TipRanks
Fri, 07 Mar 2025
ABVC BioPharma announces CFO resignation, CEO steps in as interim - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 9.4e+006 (%) |
| Held by Institutions | 21.9 (%) |
| Shares Short | 258 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.26e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 17.1 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -102.4 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 1062.72 |
| Sales Per Share | 1.54482e+006 |
| EBITDA (p.s.) | 1.12067e+006 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.4 |
| Dividend | 0 |
| Forward Dividend | 321400 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|